6.0.0.0 Ref­er­ences

  1. Knowl­er WC, Bar­rett-‍Con­nor E, Fowler SE, et al.; Di­a­betes Pre­ven­tion Pro­gram Re­search Group. Re­duc­tion in the in­ci­dence of type 2 di­a­betes with lifestyle in­ter­ven­tion or met­formin. N Engl J Med 2002;346:393–403
  2. Lind­stro¨m J, Ilanne-‍Parikka P, Pel­to­nen M, et al.; Finnish Di­a­betes Pre­ven­tion Study Group. Sus­tained re­duc­tion in the in­ci­dence of type 2 di­a­betes by lifestyle in­ter­ven­tion: fol­low-‍up of the Finnish Di­a­betes Pre­ven­tion Study. Lancet 2006;368:1673–1679
  3. Li G, Zhang P, Wang J, et al. Car­dio­vas­cu­lar mor­tal­i­ty, all-‍cause mor­tal­i­ty, and di­a­betes in­ci­dence after lifestyle in­ter­ven­tion for peo­ple with im­paired glu­cose tol­er­ance in the Da Qing Di­a­betes Pre­ven­tion Study: a 23-year fol­low-‍up study. Lancet Di­a­betes En­docrinol 2014;2:474–480
  4. Knowl­er WC, Fowler SE, Ham­man RF, et al.; Di­a­betes Pre­ven­tion Pro­gram Re­search Group. 10-year fol­low-‍up of di­a­betes in­ci­dence and weight loss in the Di­a­betes Pre­ven­tion Pro­gram Out­comes Study. Lancet 2009;374:1677–1686
  5. Nathan DM, Bar­rett-‍Con­nor E, Cran­dall JP, et al. Long-‍term ef­fects of lifestyle in­ter­ven­tion or met­formin on di­a­betes de­vel­op­ment and mi­crovas­cu­lar com­pli­ca­tions over 15-year fol­low-‍up: the Di­a­betes Pre­ven­tion Pro­gram Out­comes Study. Lancet Di­a­betes En­docrinol 2015;3:866–875
  6. Di­a­betes Pre­ven­tion Pro­gram (DPP) Re­search Group. The Di­a­betes Pre­ven­tion Pro­gram (DPP): de­scrip­tion of lifestyle in­ter­ven­tion. Di­a­betes Care 2002;25:2165–2171
  7. Ham­man RF, Wing RR, Edel­stein SL, et al. Ef­fect of weight loss with lifestyle in­ter­ven­tion on risk of di­a­betes. Di­a­betes Care 2006;29:2102– 2107
  8. Salas-Salvad ´o J, Bull ´o M, Babio N, et al.; PREDIMED Study Investigators. Reduction in the incidence of type 2 diabetes with the Mediterranean diet: results of the PREDIMED-Reus nutrition intervention randomized trial. Diabetes Care 2011;34:14–19
  9. Salas-Salvad ´o J, Guasch-Ferr ´e M, Lee C-H, Estruch R, Clish CB, Ros E. Protective effects of the Mediterranean diet on type 2 diabetes and metabolic syndrome. J Nutr 2016;146:920S– 927S
  10. Bloomfield HE, Koeller E, Greer N, MacDonald R, Kane R, Wilt TJ. Effects on health outcomes of a Mediterranean diet with no restriction on fat intake: a systematic review and meta-analysis. Ann Intern Med 2016;165:491– 500
  11. Estruch R, Ros E, Salas-Salvad ´o J, et al.; PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med 2018;378:e34
  12. Noto H, Goto A, Tsujimoto T, Noda M. Longterm low-carbohydrate diets and type 2 diabetes risk: a systematic review and meta-analysis of observational studies. J Gen Fam Med 2016; 17:60–70
  13. Ley SH, Hamdy O, Mohan V, Hu FB. Prevention and management of type 2 diabetes: dietary components and nutritional strategies. Lancet 2014;383:1999–2007
  14. Jacobs S, Harmon BE, Boushey CJ, et al. A priori-defined diet quality indexes and risk of type 2 diabetes: the Multiethnic Cohort. Diabetologia 2015;58:98–112
  15. Chiuve SE, Fung TT, Rimm EB, et al. Alternative dietary indices both strongly predict risk of chronic disease. J Nutr 2012;142:1009–1018
  16. Afshin A,Micha R, Khatibzadeh S,Mozaffarian D. Consumption of nuts and legumes and risk of incident ischemic heart disease, stroke, and diabetes: a systematic review and meta-analysis. Am J Clin Nutr 2014;100:278–288
  17. Mursu J, Virtanen JK, Tuomainen T-P, Nurmi T, Voutilainen S. Intake of fruit, berries, and vegetables and risk of type 2 diabetes in Finnish men: the Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Clin Nutr 2014;99:328–333
  18. Chen M, Sun Q, Giovannucci E, et al. Dairy consumption and risk of type 2 diabetes: 3 cohorts of US adults and an updated meta-analysis. BMC Med 2014;12:215
  19. Dehghan M, Mente A, Rangarajan S, et al.; Prospective Urban Rural Epidemiology (PURE) study investigators. Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study. Lancet. 11 September 2018 [Epub ahead of print]. DOI: 10.1016/ S0140-6736(18)31812-9
  20. Mozaf­far­i­an D. Di­etary and pol­i­cy pri­or­i­ties for car­dio­vas­cu­lar dis­ease, di­a­betes, and obe­si­ty: a com­pre­hen­sive re­view. Cir­cu­la­tion 2016;133: 187–225
  21. Park­er AR, Byham-‍Gray L, Den­mark R, Win­kle PJ. The ef­fect of med­i­cal nu­tri­tion ther­a­py by a reg­is­tered di­eti­tian nu­tri­tionist in pa­tients with predi­a­betes par­tic­i­pat­ing in a ran­dom­ized con­trolled clin­i­cal re­search trial. J Acad Nutr Diet 2014;114:1739–1748
  22. Fede­wa MV, Gist NH, Evans EM, Dish­man RK. Ex­er­cise and in­sulin re­sis­tance in youth: a meta-‍anal­y­sis. Pe­di­atrics 2014;133:e163–e174
  23. Davis CL, Pol­lock NK, Waller JL, et al. Ex­er­cise dose and di­a­betes risk in over­weight and obese chil­dren: a ran­dom­ized con­trolled trial. JAMA 2012;308:1103–1112
  24. Sigal RJ, Al­ber­ga AS, Goldfield GS, et al. Ef­fects of aer­o­bic train­ing, re­sis­tance train­ing, or both on per­cent­age body fat and cardiome-‍tabolic risk mark­ers in obese ado­les­cents: the healthy eat­ing aer­o­bic and re­sis­tance train­ing in youth ran­dom­ized clin­i­cal trial. JAMA Pe­di­atr 2014;168:1006–1014
  25. Thorp AA, King­well BA, Sethi P, Ham­mond L, Owen N, Dun­stan DW. Al­ter­nat­ing bouts of sit­ting and stand­ing at­ten­u­ate post­pran­di­al glu­cose re­spons­es. Med Sci Sports Exerc 2014;46: 2053–2061
  26. Healy GN, Dun­stan DW, Salmon J, et al. Breaks in seden­tary time: beneficial as­so­ci­a­tions with metabol­ic risk. Di­a­betes Care 2008;31:661–666
  27. Russo LM, No­bles C, Ertel KA, Chasan-‍Taber L, Whit­comb BW. Phys­i­cal ac­tiv­i­ty in­ter­ven­tions in preg­nan­cy and risk of ges­ta­tion­al di­a­betes mel­li­tus: a sys­tematic re­view and meta-‍anal­y­sis. Ob­stet Gy­necol 2015;125:576–582
  28. Grock S, Ku J-H, Kim J, Moin T. A re­view of tech­nol­o­gy-‍as­sist­ed in­ter­ven­tions for di­a­betes pre­ven­tion. Curr Diab Rep 2017;17:107
  29. Sepah SC, Jiang L, Pe­ters AL. Trans­lat­ing the Di­a­betes Pre­ven­tion Pro­gram into an on­line so­cial net­work: val­i­da­tion against CDC stan­dards. Di­a­betes Educ 2014;40:435–443
  30. Bian RR, Piatt GA, Sen A, et al. The ef­fect of tech­nol­o­gy-‍me­di­at­ed di­a­betes pre­ven­tion in­ter­ven­tions on weight: a meta-‍anal­y­sis. J Med In­ter­net Res 2017;19:e76
  31. Sepah SC, Jiang L, Pe­ters AL. Long-‍term out­comes of a Web-‍based di­a­betes pre­ven­tion pro­gram: 2-year re­sults of a sin­gle-‍arm lon­gi­tu­di­nal study. J Med In­ter­net Res 2015;17:e92
  32. Her­man WH, Ho­erg­er TJ, Bran­dle M, et al.; Di­a­betes Pre­ven­tion Pro­gram Re­search Group. The cost-‍ef­fec­tiveness of lifestyle modification or met­formin in pre­vent­ing type 2 di­a­betes in adults with im­paired glu­cose tol­er­ance. Ann In­tern Med 2005;142:323–332
  33. Chen F, Su W, Beck­er SH, et al. Clin­i­cal and eco­nom­ic im­pact of a dig­i­tal, remotely-de­liv­ered in­ten­sive be­hav­ioral coun­sel­ing pro­gram on Medi­care beneficia­ries at risk for di­a­betes and car­dio­vas­cu­lar dis­ease. PLoS One 2016;11: e0163627
  34. Di­a­betes Pre­ven­tion Pro­gram Re­search Group. The 10-year cost-‍ef­fec­tiveness of lifestyle in­ter­ven­tion or met­formin for di­a­betes pre­ven­tion: an in­tent-‍to-‍treat anal­y­sis of the DPP/ DPPOS. Di­a­betes Care 2012;35:723–730
  35. Ack­er­mann RT, Finch EA, Brizen­dine E, Zhou H, Mar­rero DG. Trans­lat­ing the Di­a­betes Pre­ven­tion Pro­gram into the com­mu­ni­ty. The DE­PLOY Pilot Study. Am J Prev Med 2008;35:357–363
  36. Balk EM, Ear­ley A, Raman G, Aven­dano EA, Pit­tas AG, Rem­ing­ton PL. Com­bined diet and phys­i­cal ac­tiv­i­ty pro­mo­tion pro­grams to pre­vent type 2 di­a­betes among per­sons at in­creased risk: a sys­tematic re­view for the Com­mu­ni­ty Pre­ven­tive Ser­vices Task Force. Ann In­tern Med 2015; 163:437–451
  37. LiR, QuS, Zhang P, et al. Eco­nom­ic eval­u­a­tion of com­bined diet and phys­i­cal ac­tiv­i­ty pro­mo­tion pro­grams to pre­vent type 2 di­a­betes among per­sons at in­creased risk: a sys­tematic re­view for the Com­mu­ni­ty Pre­ven­tive Ser­vices Task Force. Ann In­tern Med 2015;163:452–460
  38. The Com­mu­ni­ty Guide. Di­a­betes pre­ven­tion: in­ter­ven­tions en­gag­ing com­mu­ni­ty health work­ers [In­ter­net], 2016. Avail­able from https://www.thecom­mu­ni­tyguide.org/find­ings/di­a­betes-pre­ven­tion-in­ter­ven­tions-en­gag­ing-com­mu­ni­ty-health-work­ers. Ac­cessed 25 Septem­ber 2018
  39. Ely EK, Gruss SM, Luman ET, et al. A na­tion­al ef­fort to pre­vent type 2 di­a­betes: par­tic­i­pant-‍level eval­u­a­tion of CDC’s Na­tion­al Di­a­betes Pre­ven­tion Pro­gram. Di­a­betes Care 2017;40:1331–1341
  40. Yeh H-C, Dun­can BB, Schmidt MI, Wang N-Y, Bran­cati FL. Smok­ing, smok­ing ces­sa­tion, and risk for type 2 di­a­betes mel­li­tus: a co­hort study. Ann In­tern Med 2010;152:10–17
  41. Oba S, Noda M, Waki K, et al. Smok­ing ces­sa­tion in­creases short-‍term risk of type 2 di­a­betes ir­re­spec­tive of weight gain: the Japan Pub­lic Health Cen­ter-‍Based Prospec­tive Study [pub­lished cor­rec­tion ap­pears in PLoS One 2013; 8:10.1371/‍annotation/‍23aa7c42-9a4d-42a7-8f50-9d0ac4b85396]. PLoS One 2012;7:e17061
  42. Hu Y, Zong G, Liu G, et al. Smok­ing ces­sa­tion, weight change, type 2 di­a­betes, and mor­tal­i­ty. N Engl J Med 2018;379:623–632
  43. Chi­as­son J-L, Josse RG, Gomis R, Hane­feld M, Karasik A, Laak­so M; STOP-‍NIDDM Trail Re­search Group. Acar­bose for pre­ven­tion of type 2 di­a­betes mel­li­tus: the STOP-‍NIDDM ran­domised trial. Lancet 2002;359:2072–2077
  44. Torg­er­son JS, Haupt­man J, Boldrin MN, Sjo¨stro¨m L. XENi­cal in the pre­ven­tion of Di­a­betes in Obese Sub­jects (XEN­DOS) study: a ran­dom­ized study of orli­s­tat as an ad­junct to lifestyle changes for the pre­ven­tion of type 2 di­a­betes in obese pa­tients. Di­a­betes Care 2004;27:155–161
  45. le Roux CW, As­trup A, Fu­jio­ka K, et al.; SCALE Obe­si­ty Predi­a­betes NN8022-1839 Study Group. 3 years of li­raglu­tide ver­sus place­bo for type 2 di­a­betes risk re­duc­tion and weight man­age­ment in in­di­vid­u­als with predi­a­betes: a ran­domised, dou­ble-‍blind trial. Lancet 2017;389:1399–1409
  46. Ger­stein HC, Yusuf S, Bosch J, et al.; DREAM (Di­a­betes RE­duc­tion As­sess­ment with ramipril and rosigli­ta­zone Med­i­ca­tion) Trial In­ves­ti­ga­tors. Ef­fect of rosigli­ta­zone on the fre­quen­cy of di­a­betes in pa­tients with im­paired glu­cose tol­er­ance or im­paired fast­ing glu­cose: a ran­domised con­trolled trial. Lancet 2006;368:1096–1105
  47. De­Fron­zo RA, Tri­pa­thy D, Schwenke DC, et al.; ACT NOW Study. Pi­ogli­ta­zone for di­a­betes pre­ven­tion in im­paired glu­cose tol­er­ance. N Engl J Med 2011;364:1104–1115
  48. Di­a­betes Pre­ven­tion Pro­gram Re­search Group. Long-‍term safe­ty, tol­er­a­bil­i­ty, and weight loss as­so­ci­at­ed with met­formin in the Di­a­betes Pre­ven­tion Pro­gram Out­comes Study. Di­a­betes Care 2012;35:731–737
  49. Gar­vey WT, Ryan DH, Henry R, et al. Pre­ven­tion of type 2 di­a­betes in sub­jects with predi­a­betes and metabol­ic syn­drome treat­ed with phen­ter­mine and top­i­ra­mate ex­tended re­lease. Di­a­betes Care 2014;37:912–921
  50. Moin T, Schmittdiel JA, Flory JH, et al. Re­view of met­formin use for type 2 di­a­betes pre­ven­tion. Am J Prev Med 2018;55:565–574
  51. Rat­ner RE, Christophi CA, Met­zger BE, et al.; Di­a­betes Pre­ven­tion Pro­gram Re­search Group. Pre­ven­tion of di­a­betes in women with a his­to­ry of ges­ta­tion­al di­a­betes: ef­fects of met­formin and lifestyle in­ter­ven­tions. J Clin En­docrinol Metab 2008;93:4774–4779
  52. Aroda VR, Christophi CA, Edel­stein SL, et al.; Di­a­betes Pre­ven­tion Pro­gram Re­search Group. The ef­fect of lifestyle in­ter­ven­tion and met­formin on pre­vent­ing or de­lay­ing di­a­betes among women with and with­out ges­ta­tion­al di­a­betes: the Di­a­betes Pre­ven­tion Pro­gram Out­comes Study 10-year fol­low-‍up. J Clin En­docrinol Metab 2015;100:1646–1653
  53. Ra­machan­dran A, Sne­ha­latha C, Mary S, Mukesh B, Bhaskar AD, Vijay V; In­di­an Di­a­betes Pre­ven­tion Pro­gramme (IDPP). The In­di­an Di­a­betes Pre­ven­tion Pro­gramme shows that lifestyle modification and met­formin pre­vent type 2 di­a­betes in Asian In­di­an sub­jects with im­paired glu­cose tol­er­ance (IDPP-1). Di­a­betolo­gia 2006; 49:289–297
  54. Aroda VR, Edel­stein SL, Gold­berg RB, et al.; Di­a­betes Pre­ven­tion Pro­gram Re­search Group. Long-‍term met­formin use and vi­ta­min B12 deficien­cy in the Di­a­betes Pre­ven­tion Pro­gram Out­comes Study. J Clin En­docrinol Metab 2016;101:1754–1761
  55. Ali MK, Bullard KM, Say­dah S, Im­per­a­tore G, Gregg EW. Car­dio­vas­cu­lar and renal bur­dens of predi­a­betes in the USA: anal­y­sis of data from se­ri­al cross-sec­tional sur­veys, 1988–2014. Lancet Di­a­betes En­docrinol 2018;6:392–403
  56. Huang Y, Cai X, Mai W, Li M, Hu Y. As­so­ci­a­tion be­tween predi­a­betes and risk of car­dio­vas­cu­lar dis­ease and all cause mor­tal­i­ty: sys­tematic re­view and meta-‍anal­y­sis. BMJ 2016;355:i5953
  57. Bress AP, King JB, Krei­der KE, et al.; SPRINT Re­search Group. Ef­fect of in­ten­sive ver­sus stan­dard blood pres­sure treat­ment ac­cord­ing to base­line predi­a­betes sta­tus: a post hoc anal­y­sis of a ran­dom­ized trial. Di­a­betes Care 2017;40: 1401–1408
  58. Butch­er MK, Van­der­wood KK, Hall TO, Go­hdes D, Hel­ger­son SD, Har­well TS. Ca­pac­i­ty of di­a­betes ed­u­ca­tion pro­grams to pro­vide both di­a­betes self-‍man­age­ment ed­u­ca­tion and to im­ple­ment di­a­betes pre­ven­tion ser­vices. J Pub­lic Health Manag Pract 2011;17:242–247